Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”

Affiliations

Daniel Rayson: Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada
Sonal Gandhi: Division of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
Anil A. Joy: Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada
Christine Brezden-Masley: Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
Karen A. Gelmon: Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada
Sandeep Sehdev: Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
David Cescon: Department of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, Canada
Stephen Chia: Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada

Abstract

We appreciate the opportunity to respond to the comment [...]

ISSN: 1198-0052 (Print); 1718-7729 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/curroncol